Neo Ivy Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Neo Ivy Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,115	Closed	-$700K	–	420
2025 Q4	$700K	Sell	4,115 -9,815	-70%	-$1.5M	0.11%	194
2025 Q3	$1.84M	Buy	+13,930	New	+$1.67M	0.45%	77
2023 Q3	–	Sell	-3,867	Closed	-$479K	–	385
2023 Q2	$479K	Buy	+3,867	New	+$520K	0.25%	131
2022 Q4	–	Sell	-1,619	Closed	-$216K	–	442
2022 Q3	$216K	Buy	+1,619	New	+$246K	0.57%	54
2021 Q2	–	Sell	-1,556	Closed	-$256K	–	528
2021 Q1	$256K	Buy	+1,556	New	+$256K	0.28%	130
2019 Q1	–	Sell	-7,230	Closed	-$896K	–	340
2018 Q4	$896K	Buy	+7,230	New	+$1.07M	0.71%	38

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Neo Ivy Capital Management's JAZZ Position: Q1 2026 in Review

Neo Ivy Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 4,115 shares — an estimated $700K sold.

Neo Ivy Capital Management first reported a position in JAZZ in Q4 2018 and held it in 6 quarters. The position peaked at $1.84M in Q3 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Neo Ivy Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Neo Ivy Capital Management sold 4,115 Jazz Pharmaceuticals shares in Q1 2026, an estimated $700K.
Neo Ivy Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 6 quarters.
Neo Ivy Capital Management's Jazz Pharmaceuticals position peaked at $1.84M in Q3 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.